Gilead Awards $7.6 Million in Grants to Advance Health Equity in Breast Cancer

Toward Health Equity Oncology Grant ™ Supports Initiatives to Break the Cycle of Health Inequity –

Gilead Sciences, Inc. (Nasdaq: GILD) awarded $7.6 million in grant funding to 24 U.S.-based, community organizations through the newly created Toward Health Equity (THE) Oncology Grant™. The funding will support evidence-based interventions that address barriers to care and social determinants of health including patient navigator training, cultural competency training, and services combating barriers such as transportation.

"Gilead is committed to advancing health equity and supporting these vital patient advocacy organizations working to close gaps in breast cancer care," said Deborah H. Telman, Executive Vice President, Corporate Affairs and General Counsel, Gilead Sciences. "We believe our Toward Health Equity Oncology Grant awards contribute important new understanding to advance and care for anyone living with breast cancer. We look forward to seeing their dynamic, innovative programs come to life."

Breast cancer affects more American women than any other type of cancer, besides skin cancer. 1 But due to social, environmental, and economic disparities, people of color are at increased risk of developing or dying from breast cancer. 2 In 2023, an estimated 300,000 women will be diagnosed with breast cancer in the U.S. and more than 43,000 women will die from breast cancer. 3

The 2023 funding will support evidence-based interventions that focus on patient navigation and digital/mobile interventions to improve health equity. All 2023 grantees were chosen based on several criteria including their ability to create measurable and sustainable change toward health equity.

THE Oncology Grant builds on Gilead's 2022 program , which provided $5.7 million in grants to 21 U.S. organizations for programs working to advance health equity for Black people impacted by triple-negative breast cancer. The new grantees serve historically neglected and underrepresented communities including Hispanic, Jewish, LGBTQIA, Indigenous American, and others, and will work to address access disparities in the treatment of breast cancer.

The 2023 THE Oncology Grant awardees include:

  • Asociación Latina De Asistencia Y Prevención Del Cáncer De Mama
  • Association of Community Cancer Centers
  • Coalition of Blacks Against Breast Cancer
  • Family Reach Foundation
  • Franklin Square Hospital Center, Inc.
  • George Washington University
  • Harris County Hospital District Foundation
  • Mary Bird Perkins Cancer Center
  • New Orleans Musicians Assistance Foundation
  • Nueva Vida Inc.
  • Patient Advocate Foundation Inc.
  • Shanti Project Inc.
  • Share Self-Help For Women With Breast Or Ovarian Cancer, Inc.
  • Sharsheret Inc.
  • Sisters Working It Out NFP
  • St. Vincent Hospital
  • Susan G Komen Breast Cancer Foundation
  • The Ellie Fund
  • UC Davis, Comprehensive Cancer Center, Center for Advancing Cancer Health Equity
  • Vietnamese American Cancer Foundation
  • Virtua Health Foundation, Inc.
  • Women's Cancer Care and Research Program (WeCARE) at UC Davis
  • Women's Cancer Resource Center
  • Young Survival Coalition, Inc.

About Gilead Sciences

Gilead Sciences, Inc. is a biopharmaceutical company that has pursued and achieved breakthroughs in medicine for more than three decades, with the goal of creating a healthier world for all people. The company is committed to advancing innovative medicines to prevent and treat life-threatening diseases, including HIV, viral hepatitis, inflammation and cancer. Gilead operates in more than 35 countries worldwide, with headquarters in Foster City, California.

Gilead has promoted equity, particularly healthcare equity, since the company brought its first therapies to the market. Through global partnerships, Gilead's medicines today reach millions of people in low- and middle-income countries around the world. In the United States, Gilead has committed more than $100 million over 10 years through the COMPASS Initiative ® to community organizations that are working to combat HIV in the U.S. South. In 2020, Gilead launched the Racial Equity Community Impact Fund to support organizations tackling racial inequities affecting Black communities across the United States.

Gilead and the Gilead logo are trademarks of Gilead Sciences, Inc., or its related companies.
For more information about Gilead, please visit the company's website at www.gilead.com , follow Gilead on Twitter (@GileadSciences) or call Gilead Public Affairs at 1-800-GILEAD-5 or 1-650-574-3000.

1 Breast Cancer Statistics. The American Society of Clinical Oncology. Breast Cancer: Statistics | Cancer.Net . Last accessed January 31, 2023.
2 Cancer Disparities. The National Cancer Institute. Cancer Disparities - NCI . Last accessed January 31, 2023.
3 Key Statistics for Breast Cancer. The American Cancer Society. https://www.cancer.org/cancer/breast-cancer/about/how-common-is-breast-cancer.html , last accessed January 31, 2023.

Hayley Home, Media
public_affairs@gilead.com
Meaghan Smith, Media
public_affairs@gilead.com

News Provided by Business Wire via QuoteMedia

GILD
The Conversation (0)
CHMP Adopts Positive Opinion Recommending Hepcludex®  for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

CHMP Adopts Positive Opinion Recommending Hepcludex® for Full Marketing Authorization for the Treatment of Hepatitis Delta Virus

-- If Granted by the European Commission, Hepcludex will Become the Only Approved Treatment for HDV in the EU -- Gilead Sciences, Inc. (Nasdaq: GILD) today announced that the Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) has adopted a positive... Keep Reading...
Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

Gilead Remains Steadfast in Support for Hepatitis C Elimination Efforts

The recent national conversation on hepatitis C (HCV) is an encouraging step towards viral hepatitis elimination in the U.S. With its long history of leadership in viral hepatitis, Gilead continues to support efforts that focus on HCV elimination. Gilead is proud that its medicines have treated... Keep Reading...
Gilead Sciences Announces First Quarter 2023 Financial Results

Gilead Sciences Announces First Quarter 2023 Financial Results

Product Sales Excluding Veklury Increased 15% Year-Over-Year to $5.7 billion Biktarvy Sales Increased 24% Year-Over-Year to $2.7 billion Oncology Sales Increased 59% Year-Over-Year to $670 million Gilead Sciences, Inc. (Nasdaq: GILD) announced today its results of operations for the first... Keep Reading...
Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences Releases Inaugural ESG Impact Report

Gilead Sciences recently released its inaugural Environmental, Social and Governance (ESG) Impact Report. This is an evolution of our traditional Year in Review, and uses the ESG framework to highlight the successes and achievements of the prior yearThough the report itself is new, our... Keep Reading...
abigail echo-hawk

CORRECTION: Contakt World Becomes Data Partner for Health Equity Tracker Project to Improve the Collection of De-Identified Racial & Ethnic Minority Data Using Smart Health RM, Engagency, and Future Services

Enables Contakt World mission to improve health equity and reduce disparities in the fight against Covid-19 and all diseases via award-winning SaaS platformThis document corrects and updates the final paragraph in the body of this news release. No other changes were required in this... Keep Reading...

Latest Press Releases

Related News